Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccinesCoronaVac 및 ChAdox1 nCov-19(AZD1222) 백신으로 이종 프라임-부스트 백신 접종 후 면역원성 및 반응성Article Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] 95% CI 95% confidence interval Administered age age and sex antibody assigned AZD1222 binding domain booster dose Care ChAdOx1 nCoV-19 Cohort cohorts Combination Concentration control group CoronaVac COVID-19 COVID-19 pandemic effective elicited enrolled finding geometric mean ratio GMR Health Heterologous heterologous prime-boost homologous immune response immunogenicity indicated mass participant primary endpoint prime-boost interval RBD reactogenicity robust Safe the median vaccination Vaccine vaccine administration vaccine combination. while [DOI] 10.1080/21645515.2022.2052525 PMC 바로가기 [Article Type] Article
Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunityArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] appear Bayesian Beta ChAdOx1 Clinical efficacy Correlate of protection COVID-19 D614G Delta Delta VOC distribution Efficacy ENhance evaluate Evaluating finding Heterologous highlight homologous Immunity inversion Mix-match mRNA-1273 neutralizing antibody omicron pandemic phase 3 trial predicted Predictive previous study provide ranged reduction reductions in strain vaccination Vaccine variant variant of concern variants variants of concern VoC VOCs was used while Wuhan [DOI] 10.1016/j.vaccine.2022.10.011 PMC 바로가기
Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variantsArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] analysed B.1 B.1.617.2 BBIBP-CorV booster vaccination ChAdOx1-S Combination country COVID-19 elicited exhibited Gam-COVID-Vac greater Heterologous heterologous vaccination homologous immunized information mRNA-1273 mRNA-1273 vaccines Neutralizing Neutralizing antibodies non-replicative P.1 participant percentage Population protocol protocols provided SARS-CoV-2 second dose serum shortage significantly significantly lower vaccination Vaccination strategies Vaccination strategy Vaccine variant variants of concern viral vector-based [DOI] 10.1016/j.vaccine.2022.10.021 PMC 바로가기
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of OmicronArticle Published on 2022-11-052022-11-16 Journal: BMC Infectious Diseases [Category] SARS, 변종, [키워드] 95% CI Admission caused Cohort cohort analysis COVID-19 COVID-19 hospitalization COVID-19 vaccines dose doses Effectiveness elderly Elderly cohort evaluated Follow-up hazard ratio Heterologous homologous Hospitalization ICU ICU treatment Immunity individuals intensive care omicron outcome protection reduced remained restored SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 Omicron variant severe COVID-19 vaccination Vaccine waned Waning vaccine effectiveness. [DOI] 10.1186/s12879-022-07814-4 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in MiceArticle Published on 2022-11-012022-11-15 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome ancestral antibody Australia challenge coronavirus coronavirus disease COVID-19 cross-protection cross-reactivity Delta elicited homologous immunogenicity Infection K18-hACE2 K18-hACE2 mice mice Neutralizing Neutralizing antibodies neutralizing antibody omicron Omicron BA.1 remained respiratory infections SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants severe acute respiratory syndrome coronavirus 2 Strains vaccine-preventable diseases viruses zoonoses [DOI] 10.3201/eid2811.220718 PMC 바로가기
‘Mix and Match’ vaccination: Is dengue next?Article Published on 2022-10-262022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 진단, [키워드] 'Mix and match' Antigen approach benefit boost breadth cellular Cellular responses Combination COVID-19 COVID-19 pandemic demonstrated Dengue dengue virus Dengvaxia dose effective Efficacy evaluated help Heterologous HIV homologous Human Humoral immunity Immunity immunization Impact Increased immunogenicity induce match overcome priming reactogenicity regimen reported response SARS-CoV-2 SARS-CoV-2 vaccine sequence severity significantly study participant T cell TAK-003 the vaccine Trial trials TV003 vaccination Vaccine Vaccines [DOI] 10.1016/j.vaccine.2022.09.007 PMC 바로가기
Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret ModelArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] acute respiratory syndrome Airborne transmission Analysis assessment Beta changes Comparative Contact coronavirus coronavirus 2 COVID-19 Critical Delta disease evaluate ferret ferrets genomic variant Heterologous highest histopathological homologous homologous or heterologous Human in vivo infection with SARS-CoV-2 inoculated lineages lowest Mild Model offered pandemic Particle pathogenicity provided Reinfection replicated Replication replication kinetics respiratory respiratory tract risk RNA SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strains SARS-CoV-2 variant Spread Strains Surveillance the spike protein the United State Transmissibility Transmission transmitted upper respiratory tract USA-WA1/2020 variant variants virulence virus virus infection virus load WA1 while [DOI] 10.1128/mbio.02421-22 PMC 바로가기